William M. Regan

William M. Regan

Katten Muchin Rosenman LLP

Contact  |  View Bio  |  RSS

Latest Posts › Securities Exchange Act

Share:

Corporate and Financial Weekly Digest - Volume IX, Issue 30

In this issue: - Amendments to FINRA Rule 2210 Regarding Communications With the Public - Smith & Wesson Pays $2 Million to Resolve SEC Charges - Former Chief Operating Officer Settles SEC Fraud...more

8/4/2014 - Advertising Banking Sector Banks Broker-Dealer Corporate Officers Electronic Communications FINRA Misappropriation Retailers Rule 2210 SEC Securities Securities Exchange Act Securities Fraud Settlement Smith & Wesson

Life Sciences Company Obtains Dismissal of Shareholder Class Action

The US District Court for the Middle District of Tennessee recently granted BioMimetic Therapeutics Inc.’s motion to dismiss the class action against it, and denied plaintiffs leave to amend their complaint. Shareholders...more

1/23/2013 - BioMimetic Therapeutics Class Action Clinical Trials Deficiency Notices Duty to Disclose Life Sciences Securities Exchange Act Shareholder Litigation Shareholders

2 Results
|
View per page
Page: of 1